12034 Federal Register / Vol. 86, No. 38 / Monday, March 1, 2021 / Notices 

Controlled substance Drug code Schedule 

AH–7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide)) .................................................................. 9551 I 

Acetylmethadol ................................................................................................................................................................ 9601 I 

Alphamethadol ................................................................................................................................................................. 9605 I 

Ketobemidone .................................................................................................................................................................. 9628 I 

Noracymethadol ............................................................................................................................................................... 9633 I 

Para-Fluorofentanyl ......................................................................................................................................................... 9812 I 

3-Methylfentanyl .............................................................................................................................................................. 9813 I 

Alpha-methylfentanyl ....................................................................................................................................................... 9814 I 

Acetyl Fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide) ............................................................................... 9821 I 

2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide ......................................................................................... 9825 I 

3-Methylthiofentanyl ......................................................................................................................................................... 9833 I 

Cyclopropyl Fentanyl ....................................................................................................................................................... 9845 I 

Fentanyl related-compounds as defined in 21 CFR 1308.11&h) ................................................................................... 9850 I 

Amphetamine ................................................................................................................................................................... 1100 II 

Methamphetamine ........................................................................................................................................................... 1105 II 

Methylphenidate .............................................................................................................................................................. 1724 II 

Amobarbital ...................................................................................................................................................................... 2125 II 

Pentobarbital .................................................................................................................................................................... 2270 II 

Secobarbital ..................................................................................................................................................................... 2315 II 

Phencyclidine ................................................................................................................................................................... 7471 II 

Cocaine ............................................................................................................................................................................ 9041 II 

Codeine ........................................................................................................................................................................... 9050 II 

Dihydrocodeine ................................................................................................................................................................ 9120 II 

Oxycodone ....................................................................................................................................................................... 9143 II 

Hydromorphone ............................................................................................................................................................... 9150 II 

Ecgonine .......................................................................................................................................................................... 9180 II 

Hydrocodone ................................................................................................................................................................... 9193 II 

Levorphanol ..................................................................................................................................................................... 9220 II 

Meperidine ....................................................................................................................................................................... 9230 II 

Meperidine intermediate-B .............................................................................................................................................. 9233 II 

Methadone ....................................................................................................................................................................... 9250 II 

Dextropropoxyphene, bulk (non-dosage forms) .............................................................................................................. 9273 II 

Morphine .......................................................................................................................................................................... 9300 II 

Thebaine .......................................................................................................................................................................... 9333 II 

Levo-alphacetylmethadol ................................................................................................................................................. 9648 II 

Oxymorphone .................................................................................................................................................................. 9652 II 

Carfentanil ....................................................................................................................................................................... 9743 II 

Tapentadol ....................................................................................................................................................................... 9780 II 

Fentanyl ........................................................................................................................................................................... 9801 II 

The company plans to import the 

listed controlled substances for 

feasibility studies for new products and 

cross reactivity studies for existing 

products. The products will serve as 

raw materials for In Vitro Diagnostic 

quantitative assay. No other activity for 

these drug codes is authorized for this 

registration. 

Approval of permit applications will 

occur only when the registrant’s 

business activity is consistent with what 

is authorized under 21 U.S.C. 952(a)(2). 

Authorization will not extend to the 

import of the Food and Drug 

Administration-approved or nonapproved finished dosage forms for 

commercial sale. 

William T. McDermott, 

Assistant Administrator. 

[FR Doc. 2021–04147 Filed 2–26–21; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–781] 

Bulk Manufacturer of Controlled 

Substances Application: Bulk 

Manufacturer of Marihuana: Cosmic 

Light LLC 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: The Drug Enforcement 

Administration (DEA) is providing 

notice of an application it has received 

from an entity applying to be registered 

to manufacture in bulk basic class(es) of 

controlled substances listed in schedule 

I. DEA intends to evaluate this and other 

pending applications according to its 

regulations governing the program of 

growing marihuana for scientific and 

medical research under DEA 

registration. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefor, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before April 30, 2021. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. To ensure proper handling of 

comments, please reference Docket No– 

DEA–XXX in all correspondence, 

including attachments. 

SUPPLEMENTARY INFORMATION: The 

Controlled Substances Act (CSA) 

prohibits the cultivation and 

distribution of marihuana except by 

persons who are registered under the 

CSA to do so for lawful purposes. In 

accordance with the purposes specified 

in 21 CFR 1301.33(a), DEA is providing 

notice that the entity identified below 

has applied for registration as a bulk 

manufacturer of schedule I controlled 

substances. In response, registered bulk 

manufacturers of the affected basic 

class(es), and applicants therefor, may 

file written comments on or objections 

of the requested registration, as 

Federal Register / Vol. 86, No. 38 / Monday, March 1, 2021 / Notices 12035 

provided in this notice. This notice does 

not constitute any evaluation or 

determination of the merits of the 

application submitted. 

The applicant plans to manufacture 

bulk active pharmaceutical ingredients 

(APIs) for product development and 

distribution to DEA registered 

researchers. If the application for 

registration is granted, the registrant 

would not be authorized to conduct 

other activity under this registration 

aside from those coincident activities 

specifically authorized by DEA 

regulations. DEA will evaluate the 

application for registration as a bulk 

manufacturer for compliance with all 

applicable laws, treaties, and 

regulations and to ensure adequate 

safeguards against diversion are in 

place. 

As this applicant has applied to 

become registered as a bulk 

manufacturer of marihuana, the 

application will be evaluated under the 

criteria of 21 U.S.C. 823(a). DEA will 

conduct this evaluation in the manner 

described in the rule published at 85 FR 

82333 on December 18, 2020, and 

reflected in DEA regulations at 21 CFR 

part 1318. 

In accordance with 21 CFR 

1301.33(a), DEA is providing notice that 

on January 14, 2021, Cosmic Light LLC, 

5565 Ara Pahoe Avenue, Suite G, 

Boulder, Colorado 80303–1334, applied 

to be registered as a bulk manufacturer 

of the following basic class(es) of 

controlled substances: 

Controlled substance Drug 

code Schedule 

Marihuana Extract ................... 7350 I 

Marihuana ............................... 7360 I 

William T. McDermott, 

Assistant Administrator. 

[FR Doc. 2021–04180 Filed 2–26–21; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Federal Bureau of Investigation 

[OMB Number 1110–0074] 

Agency Information Collection 

Activities; Proposed eCollection 

eComments Requested; Extension, 

Without Change, of a Previously 

Approved Collection; FBI Hazardous 

Devices School Application 

AGENCY: Hazardous Device School, 

Critical Incident Response Group, 

Federal Bureau of Investigation, 

Department of Justice. 

ACTION: 60-day notice. 

SUMMARY: The Department of Justice 

(DOJ), Federal Bureau of Investigation 

(FBI), Critical Incident Response Group 

(CIRG), Hazardous Devices School 

(HDS) will be submitting the following 

information collection request to the 

Office of Management and Budget 

(OMB) for review and approval in 

accordance with the Paperwork 

Reduction Act of 1995. The proposed 

information collection is published to 

obtain comments from the public and 

affected agencies. 

DATES: Comments are encouraged and 

will be accepted for 60 days until April 

30, 2021. 

FOR FURTHER INFORMATION CONTACT: If 

you have additional comments 

especially on the estimated public 

burden or associated response time, 

suggestions, or need a copy of the 

proposed information collection 

instrument with instructions or 

additional information, please contact 

Mark H. Wall, Supervisory Management 

and Program Analyst, FBI, Hazardous 

Devices School, at telephone number 

(540) 424–4575, 7010 Redstone Road, 

Huntsville, AL 35898. 

SUPPLEMENTARY INFORMATION: Written 

comments and suggestions from the 

public and affected agencies concerning 

the proposed collection of information 

are encouraged. Your comments should 

address one or more of the following 

four points: 

—Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the Bureau of Justice 

Statistics, including whether the 

information will have practical utility; 

—Evaluate the accuracy of the agency’s 

estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

—Evaluate whether and if so how the 

quality, utility, and clarity of the 

information to be collected can be 

enhanced; and 

—Minimize the burden of the collection 

of information on those who are to 

respond, including through the use of 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms 

of information technology, e.g., 

permitting electronic submission of 

responses. 

Overview of This Information Collection 

1. Type of Information Collection: 

Extension, without change, of a 

previously approved collection. 

2. The Title of the Form/Collection: 

Federal Bureau of Investigation 

hazardous Devices School Course 

Application. 

3. The agency form number, if any, 

and the applicable component of the 

Department sponsoring the collection: 

The form number FD–731. Federal 

Bureau of Investigation (FBI). 

4. Affected public who will be asked 

or required to respond, as well as a brief 

abstract: This form is utilized by the 

FBI, Hazardous Devices School to 

information needed during a review 

process of the identification and 

qualification of prospective students, 

and to initiate a review of security 

clearance status prior to being granted 

access to law enforcement sensitive and 

classified facilities and information. 

5. An estimate of the total number of 

respondents and the amount of time 

estimated for an average respondent to 

respond: It is estimated that 1,000 

respondents will complete each form 

within approximately 45 minutes. 

6. An estimate of the total public 

burden (in hours) associated with the 

collection: There are an estimated 750 

total annual burden hours associated 

with this collection. 

If additional information is required, 

contact: Melody Braswell, Department 

Clearance Officer, United States 

Department of Justice, Justice 

Management Division, Policy and 

Planning Staff, Two Constitution 

Square, 145 N Street NE, 3E.405A, 

Washington, DC 20530. 

Dated: February 23, 2021. 

Melody Braswell, 

Department Clearance Officer for PRA, U.S. 

Department of Justice. 

[FR Doc. 2021–04189 Filed 2–26–21; 8:45 am] 

BILLING CODE 4410–02–P 

DEPARTMENT OF JUSTICE 

Notice of Proposed Settlement 

Agreement Under the Oil Pollution Act 

and Clean Water Act 

Notice is hereby given that the United 

States of America, on behalf of the 

Department of the Interior (‘‘DOI’’) 

acting through the U.S. Fish and 

Wildlife Service and the State of Iowa, 

acting through the Iowa Department of 

Natural Resources (‘‘IDNR’’) (DOI and 

IDNR collectively, the ‘‘Trustees’’), are 

providing an opportunity for public 

comment on a proposed Settlement 

Agreement (‘‘Settlement Agreement’’) 

among the Trustees and Canadian 

Pacific Railway (‘‘CP’’). 

The settlement resolves the civil 

claims of the Trustees against CP arising 

under their natural resource trustee 

authority under the Oil Pollution Act of 

1990, 33 U.S.C. 2702 and the Clean